Comparative Pharmacology
Head-to-head clinical analysis: FILSPARI versus LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FILSPARI versus LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE.
FILSPARI vs LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
Losartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors, blocking vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic inhibiting sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and peripheral resistance.
200 mg orally once daily, with or without food.
Initial: losartan 50 mg/hydrochlorothiazide 12.5 mg orally once daily. Titrate to maximum losartan 100 mg/hydrochlorothiazide 25 mg once daily. Usual maintenance: losartan 50-100 mg/hydrochlorothiazide 12.5-25 mg once daily.
None Documented
None Documented
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
Losartan: 2 hours; Active metabolite E-3174: 6-9 hours. Hydrochlorothiazide: 6-15 hours (mean 10 hours) with prolonged elimination in renal impairment.
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Losartan: 35% renal, 60% biliary/fecal; Hydrochlorothiazide: >95% renal (tubular secretion).
Category C
Category D/X
Endothelin Receptor Antagonist / ARB
ARB